These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 37831361)

  • 1. Current Insights of Nanocarrier-Mediated Gene Therapeutics to Treat Potential Impairment of Amyloid Beta Protein and Tau Protein in Alzheimer's Disease.
    Jain U; Johari S; Srivastava P
    Mol Neurobiol; 2024 Apr; 61(4):1969-1989. PubMed ID: 37831361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer's Disease.
    Mashal Y; Abdelhady H; Iyer AK
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
    Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
    Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of neuroinflammation in Alzheimer's disease via nanoparticle-loaded phytocompounds with anti-inflammatory and autophagy-inducing properties.
    Nayak V; Patra S; Rout S; Jena AB; Sharma R; Pattanaik KP; Singh J; Pandey SS; Singh RP; Majhi S; Singh KR; Kerry RG
    Phytomedicine; 2024 Jan; 122():155150. PubMed ID: 37944239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.
    Kazim SF; Iqbal K
    Mol Neurodegener; 2016 Jul; 11(1):50. PubMed ID: 27400746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Pathological Hallmarks of Alzheimer's Disease Through Nanovesicleaided Drug Delivery Approach.
    Roy R; Bhattacharya P; Borah A
    Curr Drug Metab; 2022; 23(9):693-707. PubMed ID: 35619248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of tau protein in Alzheimer's disease: The prime pathological player.
    Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
    Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine-based immunotherapy for Alzheimer's disease.
    Hoque M; Samanta A; Alam SSM; Zughaibi TA; Kamal MA; Tabrez S
    Neurosci Biobehav Rev; 2023 Jan; 144():104973. PubMed ID: 36435391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From Small Peptides to Large Proteins against Alzheimer'sDisease.
    Picone P; Sanfilippo T; Vasto S; Baldassano S; Guggino R; Nuzzo D; Bulone D; San Biagio PL; Muscolino E; Monastero R; Dispenza C; Giacomazza D
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems.
    Poudel P; Park S
    Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gold nanoparticle-capped mesoporous silica-based H
    Yang L; Yin T; Liu Y; Sun J; Zhou Y; Liu J
    Acta Biomater; 2016 Dec; 46():177-190. PubMed ID: 27619837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer's Disease.
    Ma TJ; Gao J; Liu Y; Zhuang JH; Yin C; Li P; Mao L; Xu J; Xu YX; Li YP; Zhao ZX; Yin Y
    Mini Rev Med Chem; 2018; 18(12):1035-1046. PubMed ID: 29243575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-mediated approaches for Alzheimer's disease pathogenesis, diagnosis, and therapeutics.
    Hettiarachchi SD; Zhou Y; Seven E; Lakshmana MK; Kaushik AK; Chand HS; Leblanc RM
    J Control Release; 2019 Nov; 314():125-140. PubMed ID: 31647979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
    Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
    EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.